Expert analyzes potential new pancreatic cancer breakthrough
statnews.com • • business
Key Points:
- Revolution Medicines reported a significant survival benefit in a Phase 3 trial for its experimental drug daraxonrasib in advanced pancreatic adenocarcinoma patients.
- Patients treated with daraxonrasib lived a median of 13.2 months, nearly double the 6.7 months median survival of those receiving standard chemotherapy.
- The company plans to use these results to seek FDA approval, though no specific timeline for submission has been provided.
- Experts involved in the trial, including Paul Oberstein from NYU Langone’s Perlmutter Cancer Center, have discussed the promising data on a biotech podcast.
